MoonLake Immunotherapeutics 4

Chief Scientific Officer Kristian Reich sold 52,448 Class A ordinary shares of MoonLake Immunotherapeutics (MLTX) for about $1.05 million under a Rule 10b5-1 plan.

On July 21 and 22, 2026, MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich, through indirect beneficial ownership of shares held by JeruCON Beratungsgesellschaft mbH, sold a total of 52,448 Class A ordinary shares under a prearranged Rule 10b5-1 trading plan at weighted average prices around $20 per share, for aggregate proceeds of roughly $1.05 million, reducing his indirect holdings to 2,712,298 shares while retaining a substantial ownership stake in the company.

Filing Facts

CIK

1821586

Ticker

MLTX

Form

4

Source Type

fda

Accession

0001213900-26-080869

Alert Tier

7